Compare BRID & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRID | ELOX |
|---|---|---|
| Founded | 1932 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 60.3M |
| IPO Year | 1995 | 2013 |
| Metric | BRID | ELOX |
|---|---|---|
| Price | $5.69 | $14.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | 3.1K | ★ 18.6K |
| Earning Date | 08-24-2026 | 08-12-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | N/A | ★ 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $174,257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $5.34 | $10.00 |
| 52 Week High | $8.62 | $23.40 |
| Indicator | BRID | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 36.73 |
| Support Level | $5.65 | $10.74 |
| Resistance Level | $6.23 | $14.65 |
| Average True Range (ATR) | 0.17 | 1.35 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 45.10 | 8.05 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.